Examkin

Question

Difficulty: MediumPulmonary and Critical Care

A 54-year-old man is evaluated in the intensive care unit for worsening oxygenation. He was intubated and mechanically ventilated 6 days ago due to a severe traumatic brain injury sustained in a fall. Over the last 24 hours, his fraction of inspired oxygen (FiO2) requirement has increased from 35% to 65%, and positive end-expiratory pressure (PEEP) was increased from 5 to 10 cm H2O. His temperature is 38.8°C (101.8°F), blood pressure is 110/68 mm Hg, and pulse is 115/min. Physical examination reveals thick, purulent secretions in the endotracheal tube. Lung auscultation demonstrates coarse crackles over the right lower lung field. Laboratory studies show a leukocyte count of 17,500/mm3. A portable chest radiograph reveals a new focal consolidation in the right lower lobe. Tracheal aspirate is obtained for Gram stain and culture. Which of the following are the most appropriate initial pharmacologic interventions for this patient? (Select all that apply)

  1. Intravenous piperacillin-tazobactamAnswer
  2. Intravenous vancomycinAnswer
  3. C
    Intravenous ceftriaxone
  4. D
    Intravenous furosemide
  5. E
    Intravenous daptomycin

Answer

The most appropriate initial pharmacologic interventions are intravenous piperacillin-tazobactam and intravenous vancomycin.
The correct combination includes an antipseudomonal agent (piperacillin-tazobactam) and an anti-MRSA agent (vancomycin). Ventilator-associated pneumonia is defined as pneumonia developing >48 hours after endotracheal intubation. Due to the high risk of multidrug-resistant organisms in the hospital setting, immediate empiric treatment must aggressively cover both Pseudomonas aeruginosa and MRSA until tracheal aspirate or bronchoalveolar lavage cultures can guide de-escalation.

Step-by-Step Solution

1
Evaluate the patient's new clinical signs and radiographic findings in the context of prolonged mechanical ventilation.
The combination of new fever, worsening oxygenation, purulent endotracheal secretions, leukocytosis, and a new right lower lobe consolidation occurring >48 hours after intubation establishes a clinical diagnosis of ventilator-associated pneumonia (VAP).
Identifying the correct clinical syndrome is essential to guide appropriate diagnostic testing and immediate empiric antimicrobial therapy.
2
Determine the likely pathogens responsible for the identified infection.
Pathogens causing VAP are typically multidrug-resistant, hospital-acquired organisms, with Pseudomonas aeruginosa and methicillin-resistant Staphylococcus aureus (MRSA) being among the most high-yield concerns.
Nosocomial infections require different empiric coverage compared to community-acquired infections due to differing local flora and resistance patterns in the intensive care unit.
3
Select the appropriate empiric antibiotic regimen based on the suspected pathogens.
The patient must receive an antipseudomonal beta-lactam (such as piperacillin-tazobactam, cefepime, or meropenem) and an agent active against MRSA (such as vancomycin or linezolid).
Delayed administration of appropriate broad-spectrum antibiotics in VAP is associated with increased mortality, so therapy must be initiated immediately while awaiting definitive culture data.

Key Concept

Empiric treatment of ventilator-associated pneumonia (VAP) requires dual broad-spectrum coverage targeting hospital-acquired pathogens, specifically including Pseudomonas aeruginosa and methicillin-resistant Staphylococcus aureus (MRSA).
Rate this question

Topics

Pulmonary and Critical Care

More questions from this topic